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What do you call a government that embarks on the 
biggest upheaval of the NHS in its 63 year history, at 
breakneck speed, while simultaneously trying to make 
unprecedented financial savings? The politically correct 
answer has got to be: mad.
The scale of ambition should ring alarm bells. Sir 
David Nicholson, the NHS chief executive, has described 
the proposals as the biggest change management pro-
gramme in the world—the only one so large “that you 
can actually see it from space.” (More ominously, he 
added that one of the lessons of change management is 
that “most big change management systems fail.”1) Of 
the annual 4% efficiency savings expected of the NHS 
over the next four years, the Commons health select 
committee said, “The scale of this is without precedent 
in NHS history; and there is no known example of such 
a feat being achieved by any other healthcare system in 
the world.”2 To pull off either of these challenges would 
therefore be breathtaking; to believe that you could man-
age both of them at once is deluded.
Like all the other structural reorganisations of the 
NHS, this one aims to improve health outcomes. What’s 
lacking is any coherent account of how these particular 
reforms will produce the desired effects, a point only 
underlined by the prime minister’s attempts to justify 
the reforms last week.3
This latest top down reorganisation has been whipped 
up in an awful hurry. It went unmentioned in the politi-
cal manifestos of the coalition parties before the last 
general election, was specifically excluded in pledges 
given before and after the election, and didn’t make it 
into the Coalition Agreement of 20 May 2010. Yet less 
than eight weeks later, its outline emerged in the white 
paper “Equity and excellence: liberating the NHS.”4
The NHS was unsurprisingly absent from the 2010 
election campaign because satisfaction levels with the 
NHS were at an all time high,5 and for most of the elec-
torate the NHS was a non-issue.6 In the words of Simon 
S tevens, president of global health at UnitedHealth 
Group, a company that stands to benefit from the 
reforms, “The inconvenient truth is that on most indica-
tors the English NHS is probably performing better than 
ever.”7
The reforms put general practitioners in the driving 
seat. Out go strategic health authorities and 152 primary 
care trusts and in come several hundred general prac-
titioner consortiums, responsible for commissioning 
£80bn (€95bn; $1.6bn) of NHS care from “any willing 
provider.” As Kieran Walshe, professor of health policy 
and management, described in his BMJ ed itorial, it 
comes as but the latest in a bewildering array of forms 
and structures put in place to run primary care and 
commission secondary care.8 Since the introduction 
of the internal market in 1991, there have been family 
practitioner committees, health authorities, GP fund-
holders, total purchasing consortiums, GP multifunds, 
primary care groups, primary care trusts, and external 
commissioning support agencies. Yet, crucially, wrote 
Walshe, “we have little evidence to suggest that any 
of these organisational structures for commissioning 
are better or worse than others, or that the proposed 
new consortiums will work any better than the current 
arrangements.”
Informed opinion about GP commissioning, past and 
present, has been almost universally negative. The pre-
vious government’s primary care tsar branded practice 
based commissioning “a corpse not for resuscitation.” 
Last year’s health select committee report on commis-
sioning concluded that “if reliable figures for the costs 
of commissioning prove that it is uneconomic and if it 
does not begin to improve soon, after 20 years of costly 
failure, the purchaser/provider split may need to be 
abolished.”9 This year’s health select committee report 
on commissioning doesn’t suggest abolition, but neither 
does it endorse the proposed reconfiguration as the best 
way to deliver the government’s objectives. It says that 
general practitioners should “be seen as generalists 
who draw on specialist knowledge when required, not 
as the ultimate arbiters of all com-
missioning decisions.”2
No matter how many GP con-
sortiums eventually emerge, their 
number will probably greatly 
exceed the 152 primary care trusts 
they are replacing, which brings 
a set of new challenges. Smaller 
populations increase the chances 
that a few very expensive patients 
will blow a hole in budgets. More consortiums mean that 
commissioning skills, already in short supply nation-
ally, will be spread even more thinly. Denied economies 
of scale, smaller consortiums may be tempted to cut 
corners on high quality infrastructure and manage-
ment, thereby endangering their survival. These points 
emerge clearly from an examination of 20 years of US 
experience of handing the equivalent of commissioning 
budgets to groups of doctors. Some groups had severely 
under estimated the importance of high quality profes-
sional management support in their early days and gone 
bankrupt as a result.10
What’s lacking 
is any coherent 
account of 
how these 
particular 
reforms will 
produce the 
desired effects
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Moving to consortiums will incur the costs of transi-
tion in addition to their recurring costs. On the basis of 
past National Audit Office data, Kieran Walshe has put 
the cost of the NHS reorganisation at £2-3bn,8 and the 
government’s figure is at the lower end of this range.11 
The white paper’s key financial pledge was to reduce 
the NHS’s management costs by more than 45%: GP 
consortiums would replace primary care trusts with 
administrative costs of over a billion pounds a year (for 
a population of 51 million)—and practice based commis-
sioners. Since then, potential consortiums have learnt 
that their running costs will be capped at between £25 
and £35 per head of population,12 not far off the primary 
care trust average management spend.
Slow down, you move too fast
The government’s recent “bonfire of the quangos” pro-
vides an instructive example of how a rush job doesn’t 
necessarily guarantee the best outcome. Earlier this 
month, the parliamentary select committee on public 
administration criticised the axing of 192 public bod-
ies and the merging of 118 more as poorly managed. It 
also said that this move would not deliver significant 
cost savings or better accountability—two of the govern-
ment’s key aims. The committee’s chairman said that, 
“The whole process was rushed and poorly handled and 
should have been thought through a lot more.”13
Rationalising a few hundred arm’s length bodies 
hardly compares with turning the NHS upside down, 
yet the proposed timescale for the health reforms is 
d izzying. The bill promises that all general practices 
will be part of consortiums by April 2012, yet it took six 
years for 56% of general practices to become fundhold-
ers after the introduction of the internal market. Nearly 
seven years after the first NHS trust was granted founda-
tion status, there are still more than half to go—within 
two years. And there’s more. The replacement for the 10 
strategic health authorities—the NHS Commissioning 
Board—needs to be fully operational by next April. By 
then, GP consortiums should have developed relation-
ships with local authorities, which will assume ultimate 
responsibility for public health via their new health and 
wellbeing boards, working alongside Public Health Eng-
land, a completely new entity.
The health secretary has made much of these changes 
being evolutionary rather than revolutionary. People 
“woefully overestimate the scale of the change,” he said. 
After all, practice based commissioning, choice of pro-
vider, an NHS price list, and foundation trusts already 
exist.14 True, but a week later came the revelation that 
hospitals would be allowed to undercut the NHS tariff 
to increase their business.12 Health economists queued 
up to say what a terrible idea this was, citing evidence 
that it would lead to a race to the bottom on price, which 
would threaten quality. Taken with the opening up of 
NHS contracts to European competition law, it was the 
last piece of evidence needed to convince critics that the 
government was unleashing a storm of creative destruc-
tion on to the NHS, with the imperative: compete or die.
Whatever the eventual outcome, such radical 
re organisations adversely affect service performance. As 
Kieran Walshe wrote, they are “a huge distraction from 
the real mission of the NHS—to deliver and improve the 
quality of healthcare” that can absorb a massive amount 
of managerial and clinical time and effort.8 Even the 
e arliest days of the transition have proved disruptive, 
with employees of the doomed primary care trusts and 
strategic health authorities choosing to jump ship rather 
than to go down with it.
With an estimated one billion pounds of redundancy 
money in their pockets,11 many of the survivors are likely 
to be employed by the new GP consortiums in much their 
same roles. It raises the question: if GP commissioning 
turns out to be simply primary care trust commissioning 
done by GPs, aren’t there less disruptive routes to this 
destination?15
Meanwhile, the need to begin making efficiency sav-
ings hasn’t gone away. Although the impact assessment 
of the new bill calculates that savings will have covered 
the costs of transition by 2012-13,11 overall savings 
won’t have contributed much to the £15-£20bn effi-
ciency savings required from the NHS by 2014-15.
Given their scale, securing these efficiency savings 
should take priority over the massive upheaval pro-
posed in the new bill. For the time being, we agree with 
the King’s Fund that those GPs who are successfully 
involved in practice based commissioning should be 
given real rather than indicative budgets for some serv-
ices and their performance monitored closely.16 All other 
proposals should be kept on hold, pending an evalua-
tion of whether this iteration of GP commissioning can 
bear the responsibility that the new bill seeks to place 
on it. If it turns out that it can, then the full introduction 
of the government’s ambitious health reforms will have 
been delayed a few years. If it can’t, then the country—
and its government—will have got off lightly.
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Vitamin D and bone health in children
Adequate vitamin D status is needed throughout childhood and adolescence
Osteoporotic fractures in adults are a substantial cause of 
morbidity and mortality, and they cost the health services 
about £2.3bn (€2.8bn; $3.6bn) a year in the United King-
dom and $30bn in the United States. Prevention, which 
includes manipulation of the development of bone mass 
during childhood and adolescence, is therefore impor-
tant. Increasing peak bone mass in young adults might 
have a longstanding effect on the risk of osteoporosis in 
later years. Although genetic factors account for 50-85% 
of the variance in adult bone density, modification of envi-
ronmental factors during childhood might have an effect 
on peak bone mass. One such factor is vitamin D.
In a linked systematic review and meta-analysis, 
Winzenberg and colleagues assess the impact of vitamin 
D supplementation on bone density in children.1 They 
show that overall vitamin D supplementation had no 
significant effect on bone density in the whole body, hip, 
or forearm (with a trend to a small effect in the lumbar 
spine). However, in children with low serum vitamin D 
(defined as <35 nmol/L) supplements had a significant 
effect on whole body bone mineral content and border-
line significance at the lumbar spine. The authors con-
clude that supplements are unlikely to be beneficial in 
children with normal vitamin D concentrations but could 
result in clinically useful improvements in children who 
are vitamin D deficient. The study complements previ-
ous research showing an association between vitamin 
D status and subsequent increments in bone density in 
peripubertal girls.2
What are the implications of this study for clinical prac-
tice and research given the high prevalence of vitamin D 
deficiency in children worldwide? Further research is 
important to clarify if such short term changes in bone 
density persist. The concept of peak bone mass influenc-
ing the risk of osteoporosis in adults has been a key influ-
ence on intervention studies in paediatric practice for 
many years but has recently been challenged.3 A system-
atic review of studies of calcium supplements in children 
showed that short term improvements in bone density 
were not maintained in the longer term.4 Most of the 
research to date has used dual energy x ray absorptiometry 
to assess bone density, and information about potential 
changes in bone geometry and estimated bone strength is 
limited. A recent randomised controlled trial in vitamin D 
deficient postmenarchal girls that used peripheral quan-
titative computed tomography in addition to dual energy 
x ray absorptiometry found that vitamin D supplements 
had no effect on bone density and geometry.5 Although 
bone density has been shown to be related to the risk of 
fracture in healthy children, fractures should be studied 
as an independent outcome in the short term in children 
with vitamin D deficiency and in the long term as adults.
What is the definition of vitamin D deficiency in clinical 
practice? This has been hotly debated given the current 
interest in the potential extraskeletal benefits of vitamin 
D. It has been recommended that serum concentrations 
of greater than 50 nmol/L or even 80 nmol/L should be 
regarded as vitamin D sufficiency.6 Many laboratories have 
adjusted their reference ranges for vitamin D to reflect such 
recommendations, with a consequent increase in the preva-
lence of abnormal results.
However, a recent UK consensus vitamin D position 
statement indicates there is currently no standard defini-
tion of an optimal concentration of vitamin D, and that con-
centrations below 25 nmol/L should indicate deficiency.7 
Even at this value vitamin D deficiency is still prevalent in 
children worldwide. A study of adolescent girls in Beijing 
showed a 45% prevalence of vitamin D concentrations of 
less than 12.5 nmol/L during the winter.8 The National Diet 
and Nutrition Survey of 2008-9 has not yet published the 
results of vitamin D analysis, but it is likely to be similar 
to previous data showing that 20-34% of 2 year old Asian 
children in the UK had values under 25 nmol/L.9
The most immediate problem of vitamin D and bone 
health is rickets, which is the most prevalent bone disease 
in children worldwide. A resurgence of this disease has 
occurred in many developed countries, and the prevalence 
remains high in Asia, Africa, and the Middle East. Many 
countries are trying to tackle this by ensuring that vitamin D 
supplements are provided to vulnerable groups. Healthcare 
professionals need to ensure that these are readily available 
and being taken. Experience suggests that vitamin D sup-
plementation involves logistical hurdles, and that sustained 
input is needed for this approach to translate into a reduc-
tion in the prevalence of rickets.10
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The UK currently has no reference nutrient intake for 
vitamin D in children above the age of 4 years, in contrast 
to the rest of Europe and the US,11 because it is assumed 
that exposure to sunlight results in adequate concen-
trations of vitamin D.12 However, Winzenberg and col-
leagues’ review suggests that adequate vitamin D status 
is needed throughout childhood and adolescence. This 
is unlikely to be achieved by vitamin D supplementation 
alone, and advice on sensible sun exposure and more 
extensive food fortification needs to be considered.
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Palliative care in people with chronic obstructive 
pulmonary disease
Passive acceptance of the illness has implications for end of life care  
and delivery of services 
The fact that chronic obstructive pulmonary disease 
(COPD) is a terminal illness comes as no surprise to cli-
nicians on acute medical wards, especially as the win-
ter takes hold. Why then are patients surprised when 
end of life issues are raised or referrals made to hospice 
services? In the linked study, Pinnock and colleagues 
postulate that patients passively accept their lot and see 
the increasing disability as part of normal ageing.1 The 
researchers found that, unlike patients with other dis-
eases (such as cancer and heart failure)—who can tell 
the story of how the illness occurred, events that have 
unfolded, and their current disease status2—patients 
with COPD seem to lack this narrative story. The realisa-
tion of illness, or “biographical disruption” to their life, 
is not a conscious thought for these patients. There is 
no clear point of diagnosis, especially one with a poor 
p rognosis.
This lack of biographical disruption stops patients 
from identifying COPD as a serious illness. Current strat-
egies aimed at identifying patients in their last six to 
12 months of life may fail because of this lack of a clear 
start to the illness as well as the difficulties of making an 
ac curate prognosis.
The delivery of palliative care has moved from end of 
life care centred on people with cancer to a more pro-
active and earlier intervention that includes people with 
diseases other than cancer. Current initiatives on services 
for patients with chronic lung disease have called for bet-
ter assessment of patients’ and carers’ needs and involve-
ment of palliative care services.3  4 An accurate holistic 
assessment of need can guide the delivery of care more 
effectively than projected longevity, so that those with 
the greatest need receive the specialist palliative care 
that they require. This would bypass the problem that 
clinicians face of knowing when to move to a palliative 
approach.5 
Pinnock’s concept of passive acceptance of the increas-
ing dyspnoea and disability can be considered either as a 
weary resignation or a more helpful, comfortable adapta-
tion by patients. The challenge for clinicians when seeing 
a gradual decline over many years is not to accept this as 
part of smoking related, accelerated ageing. Instead, they 
should consider when, or if, the patient is approaching 
the end of their life and how their care should be adapted. 
Awareness of this passive acceptance will help profession-
als to tailor care accordingly.
Transition points are opportunities to prompt profes-
sionals to open up discussions about the nature of COPD 
and the outlook for the future. The authors suggest poten-
tial examples, such as the point of diagnosis, the time of 
retirement for medical reasons, the point at which domi-
ciliary oxygen is needed, or during hospital admissions. 
For these transition points to be effective clinicians should 
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communicate and explain the current clinical situation 
and the available management approaches. This will 
require courage to change the current mindset of health 
professionals in particular and embrace some of the dif-
ficult conversations needed with life limiting illnesses.
Neither an acute care approach nor a palliative care 
approach can meet all the needs of this group of patients. 
A gradual integration of services allows time to adjust.6 
Evidence from patients with cancer suggests that early 
involvement of palliative care is better for patients’ quality 
of life and has no adverse impact on mortality.7 Similar 
research in people with COPD would be helpful.
The challenge will be to integrate a model that traverses 
acute and palliative care settings, is sensitive to the 
requirement for active hospital care, deals with the life 
limiting nature of the condition, and does not overwhelm 
the limited specialist palliative care services currently 
available. For example, how should clinicians recognise 
when a palliative approach is more appropriate than an 
acute medical one? And, if this is the case, whether they, 
and the other services involved, have the skills to manage 
an acutely breathless patient at home when the patient 
does not want to be admitted to hospital? This is where 
experience from palliative care services could be most 
useful.
Several research questions remain. How will patients 
perceive coming from a mindset of passive acceptance of 
their medical problem to accepting that they have a life 
limiting illness? What will be their response to discussions 
about end of life care with an uncertain prognosis? How 
and when should clinicians tackle such discussions and 
manage their own emotions, especially if they have been 
treating the patient for several years? Questions around 
service provision and symptom control, especially of dysp-
noea, remain. How can traditional palliative interventions 
developed mainly for cancer be applied to COPD?
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One nudge forward, two steps back
Why nudging might make for muddled public health and wasted resources
In the linked article, Marteau and col-
leagues offer a timely note of caution about 
“nudging”—an approach to be haviour 
change described in Nudge: Imp roving 
Decisions about Health, Wealth and 
H appiness, a book by the US academics 
Richard Thaler and Cass Sunstein—which 
is the coalition government’s preferred 
strategy for promoting public health.1
Based on an explicitly self contradictory 
concept termed “libertarian paternalism,”2 
nudging recognises that our everyday deci-
sions are often not conscious and rational. 
Much of our behaviour is automatic or follows perceived 
norms, and it relies on poor information about conse-
quences or overinterpretation of misleading information. 
Consequently, nudging is based on the principle that it is 
legitimate to influence people’s behaviour to make their 
lives healthier (paternalism), but that such influence 
should be unobtrusive and not entail compulsion (liber-
tarian). Nudges might involve subconscious cues (such as 
painting targets in urinals to improve accuracy) or correct-
ing misapprehensions about social norms (like telling us 
that most people do not drink excessively). They can alter 
the profile of different choices (such as the prominence of 
healthy food in canteens) or change which options are the 
default (such as having to opt out of rather than into organ 
donor schemes). Nudges can also create 
incentives for some choices or impose 
minor economic or cognitive costs on other 
options (such as people who quit smoking 
banking money they would have spent on 
their habit but only being able to withdraw 
it when they test as nicotine free).
As Marteau and colleagues note, despite 
the fanfares with which nudging has been 
presented in the recent public health white 
paper Healthy Lives, Healthy People, these 
ideas are far from new. Supermarkets have 
spent enormous sums on research into how 
to direct our choices in ways that serve what they define as 
our interests (in other words, their own), most obviously 
by lining check-out queues with sweets placed at children’s 
eye level.3 Meanwhile, concepts such as social norms and 
incentivisation are rooted in longstanding theories of 
health behaviour. Marteau and colleagues rightly point out 
the vagueness with which the term nudge has been used, 
its limited evidence base, and its potential for harm. They 
call for new primary research and systematic reviews to 
examine the effectiveness of public health nudges.
However, we shouldn’t rush into investigating the evi-
dence base of nudging unless it offers something that exist-
ing approaches do not. Defined negatively, nudges seem 
to be anything other than just giving people basic factual 
Cue the subconscious
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information to enable them to make more rational, con-
scious decisions, or compelling them to change behaviour. 
It isn’t clear how nudges are distinctive in any other way. 
Public health is rarely coercive (other than to prevent harm 
to third parties), generally goes beyond information giving, 
and already seeks to influence how choices are presented. 
For example, social marketing engages with emotional 
decision making using techniques borrowed from adver-
tising.4 Motivational interviewing draws on people’s need 
for cognitive consistency, and it helps people to identify 
disparities between their goals and current behaviours, 
with the aim of changing any disparate behaviours.5 Peer 
education harnesses the power of social norms by enabling 
people to spread health messages through their social 
networks.6 Structural interventions modify the physical, 
organisational, or social environment to change behav-
iour.7
Unlike nudging, all of these existing approaches are 
informed by theories that help define which interventions 
qualify as examples and identify the causal pathways 
along which they aim to operate. More research is certainly 
needed, but it should be focused on approaches with a clear 
theoretical basis and a coherent causal pathway linking the 
intervention to the desired outcome.
Furthermore, many of Thaler and Sunstein’s examples of 
nudges don’t fit with their own definition. They cite legis-
lation mandating cigarette packets to present information 
on the risks of smoking, an example of using basic factual 
information to promote behaviour change in a way that 
nudging is supposed to transcend. They also cite a pro-
gramme paying a “dollar a day” to teenage mothers con-
tingent on their having no further pregnancies; this would 
exert a considerable financial pressure on young women in 
poverty, contradicting the definition of nudges as not exert-
ing such pressures.
Nudge is an interesting book, but for its politics not its 
science. In describing nudging as libertarian paternal-
ism, it makes a strong case for state action in the context 
of co ntemporary America, where large numbers of citizens 
have been influenced by a media shaped by corporate inter-
ests to vote against governmental measures that would 
benefit them.8 Thaler and Sunstein argue for the legiti-
macy of state intervention to benefit citizens as long as it 
neither hectors nor coerces (but they acknowledge in their 
conclusions that there are no hard and fast cut-off points). 
Although persuasive, their argument rests on attacking 
a straw man. As argued above, most public health is not 
coercive (and goes beyond information giving); this is also 
surely true of most other social policies, aside from the com-
pulsion to attend school and pay taxes.
In terms of public health science, the notion of nudging 
adds nothing to existing approaches. Public health policies 
should be based on the best available evidence, but the gov-
ernment has shown a worrying tendency to undermine the 
collection of such evidence—for example, by stopping the 
National Institute for Health and Clinical Excellence from 
undertaking appraisals of several strategies to improve pub-
lic health.9 Nudge contains some eye catching ideas, but 
little progress will be made if public health policy is made 
largely on the basis of ideology and ill defined notions that 
fail to deal with the range of barriers to healthy living.
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